Cognitive enhancers: what they are, how they work and what is in the pipeline

Kalliopi Dodou; Hamde Nazar

doi:10.1211/PJ.2025.1.345276

Cognitive enhancers: what they are, how they work and what is in the pipeline

Research output: Contribution to journal › Article › peer-review

Abstract

NZT-48 was the drug of choice in the US thriller “Limitless”. The claim was that the main character, a struggling author, was able to access 100 per cent of his brain capacity instead of the “usual” 20 per cent. The film revolved around the possibilities of this increased aptitude, ranging from immediate inspiration to complete a best-selling manuscript to identifying and capitalising on trends in the stock market. The opportunities were wild and dramatic but then the withdrawal symptoms were just as extreme to drive the fast-paced drama and excitement towards maintaining a constant supply and funding a personal laboratory scientist to work on more effective derivatives1
.

Original language	English
Pages (from-to)	205-220
Number of pages	16
Journal	The Pharmaceutical Journal
Volume	290
DOIs	https://doi.org/10.1211/PJ.2025.1.345276
Publication status	Published - 23 Feb 2013
Externally published	Yes

Access to Document

10.1211/PJ.2025.1.345276Licence: Unspecified

https://pharmaceutical-journal.com/article/ld/cognitive-enhancers-what-they-are-how-they-work-and-what-is-in-the-pipelineLicence: Unspecified

Cite this

@article{171a8eeb973d496a90300106a3f16cc2,

title = "Cognitive enhancers: what they are, how they work and what is in the pipeline",

abstract = "NZT-48 was the drug of choice in the US thriller “Limitless”. The claim was that the main character, a struggling author, was able to access 100 per cent of his brain capacity instead of the “usual” 20 per cent. The film revolved around the possibilities of this increased aptitude, ranging from immediate inspiration to complete a best-selling manuscript to identifying and capitalising on trends in the stock market. The opportunities were wild and dramatic but then the withdrawal symptoms were just as extreme to drive the fast-paced drama and excitement towards maintaining a constant supply and funding a personal laboratory scientist to work on more effective derivatives1.",

author = "Kalliopi Dodou and Hamde Nazar",

year = "2013",

month = feb,

day = "23",

doi = "10.1211/PJ.2025.1.345276",

language = "English",

volume = "290",

pages = "205--220",

journal = "The Pharmaceutical Journal",

publisher = "Pharmaceutical Press",

}

TY - JOUR

T1 - Cognitive enhancers: what they are, how they work and what is in the pipeline

AU - Dodou, Kalliopi

AU - Nazar, Hamde

PY - 2013/2/23

Y1 - 2013/2/23

N2 - NZT-48 was the drug of choice in the US thriller “Limitless”. The claim was that the main character, a struggling author, was able to access 100 per cent of his brain capacity instead of the “usual” 20 per cent. The film revolved around the possibilities of this increased aptitude, ranging from immediate inspiration to complete a best-selling manuscript to identifying and capitalising on trends in the stock market. The opportunities were wild and dramatic but then the withdrawal symptoms were just as extreme to drive the fast-paced drama and excitement towards maintaining a constant supply and funding a personal laboratory scientist to work on more effective derivatives1.

AB - NZT-48 was the drug of choice in the US thriller “Limitless”. The claim was that the main character, a struggling author, was able to access 100 per cent of his brain capacity instead of the “usual” 20 per cent. The film revolved around the possibilities of this increased aptitude, ranging from immediate inspiration to complete a best-selling manuscript to identifying and capitalising on trends in the stock market. The opportunities were wild and dramatic but then the withdrawal symptoms were just as extreme to drive the fast-paced drama and excitement towards maintaining a constant supply and funding a personal laboratory scientist to work on more effective derivatives1.

UR - http://sure.sunderland.ac.uk/id/eprint/3573/

U2 - 10.1211/PJ.2025.1.345276

DO - 10.1211/PJ.2025.1.345276

M3 - Article

VL - 290

SP - 205

EP - 220

JO - The Pharmaceutical Journal

JF - The Pharmaceutical Journal

ER -

Cognitive enhancers: what they are, how they work and what is in the pipeline

Abstract

Access to Document

Other files and links

Fingerprint

Cite this